New York State Common Retirement Fund’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-12,900
Closed -$237K 3323
2020
Q4
$237K Hold
12,900
﹤0.01% 2687
2020
Q3
$237K Hold
12,900
﹤0.01% 2569
2020
Q2
$193K Hold
12,900
﹤0.01% 2658
2020
Q1
$204K Hold
12,900
﹤0.01% 2449
2019
Q4
$209K Hold
12,900
﹤0.01% 2721
2019
Q3
$192K Hold
12,900
﹤0.01% 2793
2019
Q2
$213K Hold
12,900
﹤0.01% 2786
2019
Q1
$223K Hold
12,900
﹤0.01% 2673
2018
Q4
$228K Hold
12,900
﹤0.01% 2652
2018
Q3
$234K Hold
12,900
﹤0.01% 2762
2018
Q2
$252K Buy
+12,900
New +$242K ﹤0.01% 2775
2017
Q2
Sell
-11,407
Closed -$135K 3273
2017
Q1
$135K Buy
11,407
+1
+0% +$12 ﹤0.01% 2896
2016
Q4
$149K Hold
11,406
﹤0.01% 2870
2016
Q3
$165K Buy
11,406
+2,406
+27% +$34.2K ﹤0.01% 2826
2016
Q2
$108K Hold
9,000
﹤0.01% 2962
2016
Q1
$168K Hold
9,000
﹤0.01% 2751
2015
Q4
$193K Hold
9,000
﹤0.01% 2790
2015
Q3
$152K Buy
9,000
+2,670
+42% +$66.4K ﹤0.01% 2907
2015
Q2
$237K Buy
+6,330
New +$204K ﹤0.01% 2859

New York State Common Retirement Fund's CBMG Position: Q1 2021 in Review

New York State Common Retirement Fund sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 12,900 shares — an estimated $237K sold.

New York State Common Retirement Fund first reported a position in CBMG in Q2 2015 and held it in 19 quarters. The position peaked at $252K in Q2 2018. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.

  • New York State Common Retirement Fund reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
  • New York State Common Retirement Fund sold 12,900 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $237K.
  • New York State Common Retirement Fund first reported a position in Cellular Biomedicine Group, Inc. in Q2 2015 and held it in 19 quarters.
  • New York State Common Retirement Fund's Cellular Biomedicine Group, Inc. position peaked at $252K in Q2 2018.
  • 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.

Based on New York State Common Retirement Fund's 13F filing for Q1 2021, filed 11 May 2021.